Presolicitation · SAM.gov
Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)
Department of Health and Human Services · National Institutes of Health
This notice is closed. SAM.gov archived or cancelled it, so it no longer accepts responses. It stays here for reference; SAM.gov keeps the official record. See open RFPs
Key facts
- Response deadline
- ClosedListed deadline:
- Set-aside
- Full & openAny responsible firm may compete as prime; small businesses can still team. Learn more about small-business set-asides
- NAICS
- 325412 · Pharmaceutical Preparation ManufacturingThe industry code sets the size standard you must meet to compete as a small business. Learn more about NAICS size standards
- Product / service code (PSC)
- 6505 · DRUGS AND BIOLOGICALSName from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
- Place of performance
- Bethesda, MD
- Notice type
- Presolicitation
- Posted
- Archive date
- SAM.gov removes the notice from active search after this date.
- Solicitation number
- NOI-27-000056
- SAM.gov notice ID
- 60c6fdeb7763436d9e2ac65227d95af1
- Buying organization
- Department of Health and Human Services
- National Institutes of Health
- National Institutes of Health - Cc
Source: SAM.gov Contract OpportunitiesSynced First seen Nov 9, 2026Official notice (opens SAM.gov in a new tab)
See how this RFP fits your company
Claim your free UEI profile and TeamingIndex checks every notice against your SAM.gov NAICS codes, size, set-aside status and past performance, explains the fit, and emails you new matches.
Acquisition Description:
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements.
The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year.
Show the full descriptionHide the rest of the description
Justification:
Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S.
Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo.
Requirements:
SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101)
SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260)
Period of performance/Date of Delivery:
Within 30 days of award, or mutually agreed upon.
Place of Performance or Delivery:
Place of Performance: NIH Clinical Center in Bethesda, MD
The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov
All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Plain text from SAM.gov (formatting removed; at most 20,000 characters). The official notice and its attachments govern.